Medtronic (NYSE:MDT) today announced data from the ALERT trial aimed at addressing health disparities in structural heart care.
The ALL-RISE Trial included 1930 patients enrolled across 59 global sites in North America, Asia, Europe and the Middle East. Patients presenting with coronary stenoses of intermediate significance ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results